Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Not unlike Regeneron’s acquisition of 23andMe, Predictive Oncology’s AI-driven breakthroughs reflect ... early drug discovery and enable drug development for the benefit of cancer patients ...

Sanofi is an R&D driven, AI-powered biopharma company committed ... to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees ...

The companies are seeking to enhance their competitive edge by boosting research velocity, fortifying data security and leveraging AI ... Regeneron to gain new insights that can aid in drug ...

This proprietary AI/ML platform and robust scientific methodology is the cornerstone of our business development efforts in oncology drug discovery and repurposing,” Vennare concluded. Not unlike ...

Disclaimer: This is an AI-generated summary of a press ... M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. “This is an exciting development in our obesity ...

Regeneron announced a major expansion of its biologics manufacturing ... Additionally, the company is expected to construct a continuous glucose monitoring facility in Indiana and open a new AI-driven ...

Regeneron and Sanofi (NASDAQ:SNY) are collaborating on the global development of this drug ... our conviction lies in the belief that some AI stocks hold greater promise for delivering higher ...

Regeneron will lead development and commercialisation for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments. The companies will jointly advance ...

This isn’t about accelerating drug development. That’s a public ... What happens when Regeneron partners with AI companies to model disease outcomes based on your code? What happens when ...